BTC Health Limited (ASX: BTC) acquires exclusive distribution rights for Bronchitol (R) and Aridol (R) from Pharmaxis

acquires exclusive distribution rights for Bronchitol (R) and Aridol (R) from Pharmaxis

Melbourne, July 6, 2021 AEST (ABN Newswire) – BTC Health Limited (ASX: BTC) is pleased to announce that its company in which it invests, BioImpact Pty Ltd, has acquired the exclusive distribution rights for the specialty respiratory product brands Bronchitol (R) and Aridol (R) from Pharmaxis (ASX: PXS) in Australia, New Zealand, Singapore, Malaysia, Hong Kong and South Korea (Bronchitol (R) only).

The exclusive distribution agreement comes into effect on July 1, 2021, with an initial term of 10 years and automatic renewals for subsequent terms of 3 years. Pharmaxis will continue to manufacture and supply Bronchitol (R) and Aridol (R) to BTC Health from its TGA approved plant in Sydney. In return for the distribution rights, BioImpact Pty Ltd will make a one-time payment of $ 2 million to Pharmaxis within 10 business days.

Bronchito (R) and Aridol (R) are specialty pharmaceuticals used with an inhalation device and together generate approximately $ 1.4 million in annual sales to hospitals and respiratory clinics in Australia. BTC Health will take responsibility for the promotion and sale of Bronchitol (R) and Aridol (R) to all existing respiratory clients and clinics and, in due course, will review the business case to grow on other eligible markets outside of Australia.

Bronchitol (R) is used to treat cystic fibrosis and allows patients (6 years of age and older) with the disease to help clear mucus from the lungs. It is an inhaled dry powder form of mannitol, which works by drawing water into the airways, which makes coughing easier and improves lung function. It is funded by the Australian Federal Government and is part of the Pharmaceutical Benefits Scheme (PBS). Bronchitol (R) has several advantages over other mucociliary clearance drugs, being less time consuming and more convenient to use compared to a nebulizer, increasing patient medical compliance and thus improving quality of life.

Aridol (R) is an innovative lung function test designed to help physicians diagnose and manage asthma by detecting active inflammation of the airways by measuring airway hyperresponsiveness. Clinicians rely on the Aridol (R) challenge test to diagnose asthma patients, helping to build an asthma management factory.

Dr Richard Treagus, Executive Chairman, commented “Bronchitol (R) and Aridol (R) are essential specialist respiratory products and BTC Health is pleased to ensure their continued availability in the Australian market. These products represent an important step for BTC Health towards the specialty. pharmaceuticals, being a segment that perfectly matches our established capabilities and expertise. What is important for our shareholders, this transaction will be immediately profitable. ”

Further information on Bronchitol (R) and Aridol (R) can be obtained via:

In Australia, 3,500 people have cystic fibrosis and 1 in 2,500 babies are diagnosed with the disease each year. On average, patients spend $ 22,336 per year on health care costs, rising to an average of $ 55,2,932 per year for a Category 4 patient. In Australia, 2.7 million people are diagnosed with asthma, resulting in equivalent to 11.2% of the population or 1 in 9 Australians. Aridol (R) is funded by respiratory clinics and / or fully funded by patients who undertake the airway challenge test. Aridol (R) is also used by clinicians to confirm that patients with asthma are complying with their prescribed asthma management plan. The estimated cost of asthma in Australia in 2015 was $ 11,740 per person.

About BTC Health Limited

BTC Health LimitedBTC Health (ASX: BTC) is an ASX listed entity and is a common development fund, registered under the 1992 Common Development Funds Act. It is a fast-growing company focused on providing patients with innovative, world-class medical products. in Australia and New Zealand.

Related companies

Pharmaxis SA
BTC Health Limited

ABN News Wire
This page has been viewed:

About John Tuttle

Check Also

Quit vaping programs are becoming essential for today’s workers

Vaping has become a growing concern in the workplace, with nearly 11 million American adults …

Leave a Reply

Your email address will not be published.